Sign In / Join

close

Conferences

Our Conferences articles contain the latest coverage of medical advancements from recent academic conferences.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

Promising Results from Arlo-cel CAR T in Myeloma

January 09, 2025

Learn about a. new CAR T product, arlo-cel, that targets GPRC5D on multiple myeloma cells. The early results are extremely encouraging.

Barriers to Proper Genetic Testing? Understanding FISH Access

January 08, 2025

Learn what's keeping people from truly understanding their myeloma genetics as many experience barriers to the incredibly helpful FISH test.

Addressing Disparities in Multiple Myeloma Care: What It Means for Patients

January 07, 2025

Learn what Black myeloma patients, caregivers and advocates suggest to solve some of the healthcare disparities that exist today.

CAR T-Cell Therapy: Long-Term Side Effects and Patient Outcomes from ASH 2024

December 23, 2024

CAR T-cell therapy's long-term effects, patient-reported outcomes, and infection management strategies from ASH 2024. Expert insights from leading oncologists.

Studying Quality of Life With and Without Elotuzumab in Newly Diagnosed Myeloma

December 18, 2024

Learn how newly diagnosed myeloma patients felt their quality of life was impacted both on and off regimens with elotuzumab.

What Can Be Done to Predict Optimal CAR-T Responses?

December 17, 2024

Learn how previous therapies, including BCMA-directed treatment and stem cell transplants, can affect CAR T cell therapy outcomes in multiple myeloma.

Does 24-Hour Urine Testing Add Value to Myeloma Response Results?

December 16, 2024

Learn about the study presented in ASH 2024 that explored the idea of urine-free clinical trial response assessments in multiple myeloma.

Effects of Eating Fiber, Plant-Based Diet, Keto Diet, and Smoking on Certain Blood Cancers

December 10, 2024

Read research highlights from the ASH 2024 conference how certain lifestyle choices affect blood cancers.

The Best of ASH 2024

December 10, 2024

Discover the board's selection of best abstracts at the 66th annual ASH conference.

Landmark Study Shows Daratumumab Significantly Delays Progression in Smoldering Myeloma

December 10, 2024

The AQUILA trial shows Darzalex is effective in high-risk smoldering multiple myeloma, with 63% of patients progression-free at 5 years.

Upcoming Events

Maintaining Oral Health During Cancer Treatment and Beyond

Jan 23 / 14:00 EST

The Future of MRD Testing: Why It Matters for Multiple Myeloma Patients and What Comes Next

Jan 30 / 13:00 EST

Bi-Monthly Blood Cancer Financial Q&A: Expert Answers to Your Treatment Costs and Support Questions

Feb 04 / 13:00 EST

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Conferences

Recent Articles

Promising Results from Arlo-cel CAR T in Myeloma

Barriers to Proper Genetic Testing? Understanding FISH Access

Addressing Disparities in Multiple Myeloma Care: What It Means for Patients

CAR T-Cell Therapy: Long-Term Side Effects and Patient Outcomes from ASH 2024

Studying Quality of Life With and Without Elotuzumab in Newly Diagnosed Myeloma

What Can Be Done to Predict Optimal CAR-T Responses?

Does 24-Hour Urine Testing Add Value to Myeloma Response Results?

Effects of Eating Fiber, Plant-Based Diet, Keto Diet, and Smoking on Certain Blood Cancers

The Best of ASH 2024

Landmark Study Shows Daratumumab Significantly Delays Progression in Smoldering Myeloma

Trending Articles

Promising Results from Arlo-cel CAR T in Myeloma

Cecelia Butler Johnson: Two Decade Survivor of Myeloma and Breast Cancer

Barriers to Proper Genetic Testing? Understanding FISH Access

CAR T-Cell Therapy: Long-Term Side Effects and Patient Outcomes from ASH 2024

What Is the Best Consolidation/Maintenance Therapy for People with Myeloma?

Upcoming Events

Maintaining Oral Health During Cancer Treatment and Beyond

The Future of MRD Testing: Why It Matters for Multiple Myeloma Patients and What Comes Next

Bi-Monthly Blood Cancer Financial Q&A: Expert Answers to Your Treatment Costs and Support Questions

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Follow Us

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info

Conferences

Recent Articles

Promising Results from Arlo-cel CAR T in Myeloma

Barriers to Proper Genetic Testing? Understanding FISH Access

Addressing Disparities in Multiple Myeloma Care: What It Means for Patients

CAR T-Cell Therapy: Long-Term Side Effects and Patient Outcomes from ASH 2024

Studying Quality of Life With and Without Elotuzumab in Newly Diagnosed Myeloma

What Can Be Done to Predict Optimal CAR-T Responses?

Does 24-Hour Urine Testing Add Value to Myeloma Response Results?

Effects of Eating Fiber, Plant-Based Diet, Keto Diet, and Smoking on Certain Blood Cancers

The Best of ASH 2024

Landmark Study Shows Daratumumab Significantly Delays Progression in Smoldering Myeloma

Trending Articles

Promising Results from Arlo-cel CAR T in Myeloma

Cecelia Butler Johnson: Two Decade Survivor of Myeloma and Breast Cancer

Barriers to Proper Genetic Testing? Understanding FISH Access

CAR T-Cell Therapy: Long-Term Side Effects and Patient Outcomes from ASH 2024

What Is the Best Consolidation/Maintenance Therapy for People with Myeloma?

Upcoming Events

Maintaining Oral Health During Cancer Treatment and Beyond

The Future of MRD Testing: Why It Matters for Multiple Myeloma Patients and What Comes Next

Bi-Monthly Blood Cancer Financial Q&A: Expert Answers to Your Treatment Costs and Support Questions

Get the latest thought leadership on your Multiple Myeloma delivered straight

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Follow Us

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info